Chloroquine and nanoparticle drug delivery

A promising combination

Joe Pelt, Sara Busatto, Mauro Ferrari, E Aubrey Thompson, Kabir Mody, Joy Wolfram

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Clinically approved cancer therapies include small molecules, antibodies, and nanoparticles. There has been major progress in the treatment of several cancer types over recent decades. However, many challenges remain for optimal use of conventional and nanoparticle-based therapies in oncology including poor drug delivery, rapid clearance, and drug resistance. The antimalarial agent chloroquine has been found to mitigate some of these challenges by modulating cancer cells and the tissue microenvironment. Particularly, chloroquine was recently found to reduce immunological clearance of nanoparticles by resident macrophages in the liver, leading to increased tumor accumulation of nanodrugs. Additionally, chloroquine has been shown to improve drug delivery and efficacy through normalization of tumor vasculature and suppression of several oncogenic and stress-tolerance pathways, such as autophagy, that protect cancer cells from cytotoxic agents. This review will discuss the use of chloroquine as combination therapy to improve cancer treatment.

Original languageEnglish (US)
JournalPharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Chloroquine
Nanoparticles
Pharmaceutical Preparations
Neoplasms
Cellular Microenvironment
Cytotoxins
Autophagy
Antimalarials
Drug Resistance
Therapeutics
Macrophages
Antibodies
Liver

Keywords

  • Autophagy
  • Cancer
  • Chloroquine
  • Liver
  • Nanomedicine
  • Vasculature

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Chloroquine and nanoparticle drug delivery : A promising combination. / Pelt, Joe; Busatto, Sara; Ferrari, Mauro; Thompson, E Aubrey; Mody, Kabir; Wolfram, Joy.

In: Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

@article{61e66f559dc84594937bbb10c2ba5bd2,
title = "Chloroquine and nanoparticle drug delivery: A promising combination",
abstract = "Clinically approved cancer therapies include small molecules, antibodies, and nanoparticles. There has been major progress in the treatment of several cancer types over recent decades. However, many challenges remain for optimal use of conventional and nanoparticle-based therapies in oncology including poor drug delivery, rapid clearance, and drug resistance. The antimalarial agent chloroquine has been found to mitigate some of these challenges by modulating cancer cells and the tissue microenvironment. Particularly, chloroquine was recently found to reduce immunological clearance of nanoparticles by resident macrophages in the liver, leading to increased tumor accumulation of nanodrugs. Additionally, chloroquine has been shown to improve drug delivery and efficacy through normalization of tumor vasculature and suppression of several oncogenic and stress-tolerance pathways, such as autophagy, that protect cancer cells from cytotoxic agents. This review will discuss the use of chloroquine as combination therapy to improve cancer treatment.",
keywords = "Autophagy, Cancer, Chloroquine, Liver, Nanomedicine, Vasculature",
author = "Joe Pelt and Sara Busatto and Mauro Ferrari and Thompson, {E Aubrey} and Kabir Mody and Joy Wolfram",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.pharmthera.2018.06.007",
language = "English (US)",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Chloroquine and nanoparticle drug delivery

T2 - A promising combination

AU - Pelt, Joe

AU - Busatto, Sara

AU - Ferrari, Mauro

AU - Thompson, E Aubrey

AU - Mody, Kabir

AU - Wolfram, Joy

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Clinically approved cancer therapies include small molecules, antibodies, and nanoparticles. There has been major progress in the treatment of several cancer types over recent decades. However, many challenges remain for optimal use of conventional and nanoparticle-based therapies in oncology including poor drug delivery, rapid clearance, and drug resistance. The antimalarial agent chloroquine has been found to mitigate some of these challenges by modulating cancer cells and the tissue microenvironment. Particularly, chloroquine was recently found to reduce immunological clearance of nanoparticles by resident macrophages in the liver, leading to increased tumor accumulation of nanodrugs. Additionally, chloroquine has been shown to improve drug delivery and efficacy through normalization of tumor vasculature and suppression of several oncogenic and stress-tolerance pathways, such as autophagy, that protect cancer cells from cytotoxic agents. This review will discuss the use of chloroquine as combination therapy to improve cancer treatment.

AB - Clinically approved cancer therapies include small molecules, antibodies, and nanoparticles. There has been major progress in the treatment of several cancer types over recent decades. However, many challenges remain for optimal use of conventional and nanoparticle-based therapies in oncology including poor drug delivery, rapid clearance, and drug resistance. The antimalarial agent chloroquine has been found to mitigate some of these challenges by modulating cancer cells and the tissue microenvironment. Particularly, chloroquine was recently found to reduce immunological clearance of nanoparticles by resident macrophages in the liver, leading to increased tumor accumulation of nanodrugs. Additionally, chloroquine has been shown to improve drug delivery and efficacy through normalization of tumor vasculature and suppression of several oncogenic and stress-tolerance pathways, such as autophagy, that protect cancer cells from cytotoxic agents. This review will discuss the use of chloroquine as combination therapy to improve cancer treatment.

KW - Autophagy

KW - Cancer

KW - Chloroquine

KW - Liver

KW - Nanomedicine

KW - Vasculature

UR - http://www.scopus.com/inward/record.url?scp=85048926741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048926741&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2018.06.007

DO - 10.1016/j.pharmthera.2018.06.007

M3 - Article

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -